Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging
Details
Publication Year 2024-04,Volume 19,Issue #2,Page 261-279
Journal Title
PET Clinics
Publication Type
Review
Abstract
Although positron emission tomography/computed tomography (PET/CT) underwent rapid growth during the last quarter-century, becoming a new standard-of-care for imaging most cancer types, CT and bone scan remained the gold standard for patients with prostate cancer. This occurred as 2-fluorine-18-fluoro-2-deoxy-d-glucose was perceived to have a limited role owing to low sensitivity in many patients. A resurgence of interest occurred with the use of fluorine-18-sodium-fluoride PET/CT as a replacement for bone scintigraphy, and then choline, fluciclovine, and dihydrotestosterone (DHT) PET/CT as prostate "specific" radiotracers. The last decade, however, has seen a true revolution with the meteoric rise of prostate-specific membrane antigen PET/CT.
Publisher
Elsevier
Keywords
Male; Humans; *Positron Emission Tomography Computed Tomography/methods; *Prostatic Neoplasms/diagnostic imaging; Fluorine Radioisotopes; Molecular Imaging; Gallium Radioisotopes; Pet; Pet/ct; Psma; Prostate-specific membrane antigen; Radiopharmaceuticals; Radiotracers
Department(s)
Cancer Imaging
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-04-02 01:32:28
Last Modified: 2024-04-02 01:32:43

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙